Dawn Health is collaborating with Merck, a leading pharmaceutical company, to develop a digital platform for managing Growth Hormone Disorders (GHD). Over the next two years, the partnership aims to create a cutting-edge, user-centric solution that leverages the latest AI technologies for growth predictions and advanced personalization. This digital product will enhance user experience, adherence, and treatment outcomes for tens of thousands of patients across more than 40 countries.
The platform will support children and young adults with GHD, as well as their caregivers, providing tools and assistance in both home and clinical settings. Emphasizing patient-centricity, the project will involve speaking with patients to understand their unmet needs and gathering insights from caregivers and healthcare professionals. This approach ensures the solution effectively empowers and supports those living with GHD throughout their treatment journey.
Dawn Health is proud to have been selected by Merck for this significant collaboration. The partnership has already begun with successful workshops and inspiring discussions. Dawn Health, a global leader in digital health specializing in software as a medical device (SaMD) and digital therapeutics (DTx), is excited to work with Merck's dedicated team to improve the lives of people living with GHD.
Click here to read the original news story.